<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235222</url>
  </required_header>
  <id_info>
    <org_study_id>CREPATS 05-01-PHOENIX</org_study_id>
    <nct_id>NCT00235222</nct_id>
  </id_info>
  <brief_title>Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY</brief_title>
  <official_title>Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <brief_summary>
    <textblock>
      Lipodystrophie, peripheral neuropathy and mitochondrial toxicity has been associated to
      stavudine at standard doses The aim of this study is to evaluate the efficacy of reduced
      doses of stavudine (30 mg b.i.d.) in HIV patients with controlled viral load and body weight
      &gt; 60 kg, receiving an antiretroviral therapy containing stavudine 40 mg b.i.d.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stavudine is a nucleoside inhibitor larged used in HIV treatments and has been associated to
      mithocondrial toxicity. As it is still largely used in developping countries,the evaluation
      of reducing dose is of importance.

      A single-arm open pilot 48 weeks study to evaluate the capacity of a switch from d4T 40 mg to
      30 mg bid in patients with body weight &gt; 60kg to maintain full viral load suppression.
      Clinical and biological evaluations were carried out at baseline, W24 and W48. Primary
      end-point is viral load suppression (&lt;400 coies/ml) at W24.

      Secondary end-points are : Evolution of CD4 count at W24 and W48, neurological examination at
      Baseline, W24 and W48, metabolic parameters and stavudine PK at W24.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2004</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with viral load &lt; 400 copies/ml at week S24</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and biological safety of the reduced doses of stavudine at week 24. Percentage of patients with viral load &lt; 400 copies/ml at week 48, evolution of Cd4 count from baseline to W24 and 48. Evolution of metabolic parameters from baseline to W24 and</measure>
  </secondary_outcome>
  <enrollment>57</enrollment>
  <condition>HIV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stavudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV patients

          -  Patients with an antiretroviral treatment containing stavudine at standard doses (40mg
             BID) for at least 3 months

          -  Patients with viral load &lt; 400 copies/ml for at least 3 months

        Exclusion Criteria:

          -  Patients receiving an antiretroviral therapy containing stavudine at 30mg BID

          -  Current Opportunistic Infection

          -  Current chemotherapy or under cytokines treatment (PEG, INF, IL2)

          -  Pregnant or feeding Women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela BONMARCHAND, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Service de médecine Interne Hôpital Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hocine AIT-MOHAND, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Service de Maladies Infectieuses Hôpital Pitié Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Maladies Infectieuses Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>October 24, 2005</last_update_submitted>
  <last_update_submitted_qc>October 24, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2005</last_update_posted>
  <keyword>Stavudine</keyword>
  <keyword>Reduced dose of stavudine</keyword>
  <keyword>Viral load</keyword>
  <keyword>Peripheral neuropathy</keyword>
  <keyword>Treatment Experienced</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

